According to public information, Meihua International was registered in the Cayman Islands on November 10, 2020 and is a supplier of Class I, II and III disposable medical devices. Headquartered in Touqiao Town, Yangzhou City, Jiangsu Province, the company has a product distribution network covering Europe, North America, South America, Asia, Africa and Oceania, and currently has nearly 2095 dealers in mainland China.

Meihua International operates more than 920 kinds of products, including disposable infusion pumps and anesthetic puncture kits. The main income comes from two aspects, one is the direct sale of own-brand medical devices, and the other is the resale of medical devices produced by other manufacturers. From 2019 to 2020, the company recorded revenue of $79.6261 million and $89.061 million, respectively.

It is worth mentioning that Touqiao Town, Yangzhou City, where Meihua International headquarters is located, is known as "the hometown of Medical equipment consumables in China". It is one of the four major distribution centers of medical equipment consumables in China, and it is also the national key epidemic prevention material production base of COVID-19. In 2020, with its contribution to the national export of masks and medical latex gloves, Touqiao Town was awarded the national advanced collective in the fight against COVID-19 epidemic. Orders for masks and other products increased significantly in 2020, with disposable mask revenue soaring from $200000 in 2019 to $10 million in 2020, according to the prospectus.

Although Meihua International has a large number of export products, its main market is still in China, with 2869 customers in 30 countries around the world. At present, Meihua International mainly adopts the distribution model, which contributes nearly 90% of the company's revenue, accounting for 88.15% and 89.41% of revenue in 2019 and 2020, respectively. However, it is surprising that Meihua International has not signed a long-term cooperation agreement with its distribution customers. This is virtually a potential risk, once Meihua International is unable to establish and maintain sufficient sales channels to meet the growing demand for products, it will have a very negative impact on its performance.

Some securities analysts believe that with the severity of the epidemic and the rapid spread of O'Micron, there may be a wave of large-scale procurement of masks and epidemic prevention supplies around the world. This is a rare opportunity for Meihua International, which is mainly engaged in overseas medical exports, and judging from the epidemic prevention efforts of many countries in the United States and Europe, this situation is very difficult to change in the short term, and Meihua International will usher in a larger space for growth.

On the whole, thanks to the fact that Meihua's international business mainly comes from overseas medical exports, the development of enterprises is still on an upward channel. with the improvement of the economic level and the gradual improvement of the medical insurance system, the market scale of disposable medical devices is gradually expanding. there is still a lot of room for growth in the future, or the opportunity to usher in the post-epidemic era.

In addition, Meihua International successfully landed in US stocks, opening the dusty way of listing US stocks for a long time, which is undoubtedly a shot in the arm for Chinese companies. Recently, a number of Chinese enterprises have delivered their SEC forms: Trinity kitchenware, home insurance, Youchuang ePark Intelligent Technology and so on. Meihua International has successfully listed on the stock market, giving Chinese companies listed in the United States in 2022 a good start.